The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.
G. Shapiro
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
P. LoRusso
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
E. L. Kwak
No relevant relationships to disclose
J. M. Cleary
No relevant relationships to disclose
L. Musib
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
C. Jones
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
A. de Crespigny
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
M. Belvin
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
M. McKenzie
Employment or Leadership Position - Genentech
M. R. Gates
Employment or Leadership Position - Genentech
I. T. Chan
Employment or Leadership Position - Genentech
J. C. Bendell
No relevant relationships to disclose